News
SUPN ▼ -0.1% - Supernus Pharmaceuticals, Inc.
SUPN ▼ -0.1% - Supernus Pharmaceuticals, Inc.
$SUPN - Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
Supernus Pharmaceuticals' stock was essentially flat today despite the company announcing a partnership between Olympic athlete Chloe Kim and its Qelbree medication. The collaboration appears designed to raise awareness around Qelbree, which the company identifies as the leading prescribed branded non-stimulant ADHD treatment. The minimal stock movement suggests investors viewed the marketing initiative as routine business activity rather than a material catalyst for the company.
31-AUG-2026 08:30 AM ET
Share this post
More filings for $SUPN
SUPN ▲ +0.7% - Supernus Pharmaceuticals, Inc.Sep 2, 2026SUPN - Supernus Pharmaceuticals, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026
View full $SUPN filing history →💬 Comments
Loading comments…
Leave a comment
